10594483 - GAU: 1621

Receipt date: 05/09/2007
Express Mail Label No.: EV942366585US
Date of Deposit: May 9, 2007

Attorney Docket No. 24852-505 NATL
Page 1 of 2

Please type a plus sign (+) in this box +

MAY 0 9 2007

PTO/SB (12-97)
OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number ed Form 1449/PTO Application Number 10/594,483 International Application Number PCT/US05/011463 I.A. Filing Date April 5, 2005 INFORMATION DISCLOSURE Priority Date April 5, 2004 First Named Inventor STATEMENT BY APPLICANT Miller Group Art Unit / Conf. No.: Not Yet Assigned S. Kumar Net-Yet-Assigned (use as many sheets as necessary) Examiner Name Attorney Docket Number 24852-505 NATL

U.S. PATENT DOCUMENTS								
Exam Initials	Cite No.	Document No.	Issue Date 06/11/85	Name of Patentee(s) or Applicant(s) Eppstein, et al.	Class	Sub Class 2	Filing Date 07/08/82	
/S.K./	A1				514			
	A2	5,369,108	11/29/94	Breslow, et al.	514	266	10/04/91	
T	A3	5,608,108	03/04/97	Marks, et al.	562	621	04/17/95	
	A4	5,700,811	12/23/97	Breslow, et al.	514	314	05/19/94	
\top	A5	5,932,616	08/03/99	Breslow, et al.	514	532	04/04/94	
	A6	6,087,367	07/11/00	Breslow, et al.	514	266	05/18/99	
	A7	6,511,990	01/28/03	Breslow, et al.	514	314	08/24/00	
	A8	7,126,001	10/24/06	Breslow, et al.	546	171	10/25/02	
T	A8	2003/0235588	12/25/03	Richon, et al.	514	575	02/14/03	
1/	A9	2004/0087657	05/06/04	Richon, et al.	514	575	10/16/02	
W-	A10	2004/0266818	12/30/04	Breslow, et al.	514	310	04/01/04	

	FOREIGN PATENT DOCUMENTS							
Ini	am tlais	Cite Fore		gn Patent Document Number	Name of Patentee(s) or Applicant(s)	Date of Publication	English Yes No	
75	5.K./	B1	WO 97/11366		Merck & Co., Inc.	March 27, 1977	X	
		B2	wo	98/48825	The Salk Institute for Biological Studies	November 5, 1998	Х	
		B3	wo	00/08048	Fujisawa Pharmaceuticals Co., Ltd.	February 17, 2000	Х	
		B4	wo	05/053610	Aton Pharma, Inc.	June 16, 2005	Х	
1	7	B5	wo	05/097747	Aton Pharma, Inc.	October 20, 2005	Х	
7	V-	B6	wo	05/348800	Aton Pharma, Inc.	April 21, 2005	Х	

	OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS					
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.				
/S.K./	C1	Abe, E., et al., Proc. Natl. Acad. Sci. (USA) 78:4990-4994 (1981)				
	C2	Andrews et al., International J. Parasitology 30,761-768 (2000)				
	C3	Archer, S. et al., PNAS 95:6791-96 (1998)				
	C4	Berge, et al., J. Pharm. Sci., 66:1-19 (1977).				
	- C5	Brosch et al., Plant Cell 7, 1941-1950 (1995)				
	C6	Butler, L.M. et al., Cancer Res. 60:5165-5170 (2000)				
	C7	Cohen, L.A. et al., Anticancer Research 19:4999-5006 (1999)				
	C8	Cousens et al., J. Biol. Chem. 254,1716-1723 (1979)				
	C9	Darkin-Rattray et al., Proc. Natl. Acad. Sci. USA 93,13143-13147 (1996)				
1	C10	Dressel, U. et al., Anticancer Research 20(2A):1017-22 (2000)				
V	C11	Ebert, P. S., et al. Cancer Res. 36: 1809-1813 (1976)				

Express Mail Label No.: EV942366585US Date of Deposit: May 9, 2007

Attorney Docket No. 24852-505 NATL Page 2 of 2

	OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS					
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.				
/S.K./	C12	Finnin, M.S., et al., Nature 401:188-193 (1999)				
	C13	Frey et al, Bioorganic & Med. Chem. Lett., 12, 3443-3447 (2002)				
	C14	Friend, C., et al., Proc. Natl. Acad. Sci., U. S., 68:378-382 (1971)				
	C15	Grunstein, M., Nature, 389: 349-52 (1997)				
	C16	Guan et al., Cancer Research, 60,749-755 (2000)				
	C17	Hayashi, M., et al., Gann 70: 235-238 (1979)				
	C18	Huberman, E. et al., Proc. Natl. Acad. Sci. (USA) 76: 1293-1297 (1979)				
	C19	Kijima et al., J Biol. Chem. 268,22429-22435 (1993)				
	C20	Kim et al., Oncogene, 18: 2461-2470 (1999)				
	C21	Koghe et al., Biochem. Pharmacol. 56: 1359-1364 (1998)				
	C22	Kwon et al., PNAS 95: 3356-3361 (1998)				
	C23	Lea et al., Anticancer Research, 15, 879-873 (1995)				
	C24	Lin, R.J. et al., Nature 391:811-14 (1998)				
	C25	Lotem, J., et al., Int. J. Cancer 15: 731-740 (1975)				
\neg	C26	Lotem, J. et al., Proc. Natl. Acad. Sci. (USA) 76: 5158-5162 (1979)				
	C27	Marks, P. et al., Cancer Res. 47:659 (1987)				
\neg	C28	Marks, P.A. et al., J. Natl. Cancer Inst., 92:1210-1215 (2000)				
	C29	McBain et al., Biochem. Pharm. 53: 1357-1368 (1997)				
\neg	C30	Metcalf, D., et al., Science, 229: 16-22 (1985)				
\neg	C31	Morin, M. J., et al., Cancer Res. 44: 2807-2812 (1984)				
_	C32	Nakajima et al., Ex. Cell Res. 241,126-133 (1998)				
_	C33	Qiu et al., Mol. Biol. Cell 11, 2069-2083 (2000)				
\neg	C34	Reuben, R. C., et al., Proc. Natl. Acad. Sci. (USA) 73: 862-866 (1976)				
\neg	C35	Richon et al., Proc. Natl. Acad. Sci. USA, 93:5705-5708 (1996)				
-	C36	Richon, V. M. et al., Proc. Natl. Acad. Sci., USA, 95:3003-3007 (1998)				
\top	C37	Sachs, L., Nature (Lond.) 274: 535 (1978)				
\neg	C38	Saito et al., Proc. Natl. Acad. Sci. USA 96, 4592-4597 (1999)				
\neg	C39	Scher, W. et al., Exp. Hematol. 11: 490-498 (1983)				
_	C40	Scher, W., et al., Biochem. & Biophys. Res. Comm. 109: 348-354) (1982)				
_	C41	Schwartz, E. L. et al., Cancer Res. 42: 2651-2655 (1982)				
	C42	Schwartz, E. L., et al., Cancer Res. 43: 2725-2730 (1983)				
	C43	Schwartz, E. L., et al., Proc. Am. Assoc. Cancer Res. 24: 18 (1983)				
1	C44	Su et al., Cancer Research, 60: 3137-3142 (2000)				
	C45	Sugano, H., et al., Bibl. Hematol. 39: 943-954 (1973)				
	C46	Takenaga, K., et al., Cancer Res. 40: 914-919 (1980)				
	C47	Tanaka, M., et al., Proc. Natl. Acad. Sci. (USA) 72: 1003-1006 (1975)				
	C48	Terada, M., et al., Proc. Natl. Acad. Sci. (USA) 75: 2795-2799 (1978)				
	C49	Van Lint, C. et al., Gene Expression 5:245-53 (1996)				
	C50	Wang et al., Cancer Research 59, 2766-2799 (1999)				
1/	C51	Yoshida, M. et al., J. Biol. Chem. 265:17174-17179, (1990)				
-W-	C52	International Search Report for PCT/US05/011463 mailed July 26, 2005				

*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. _____, filed _____, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature	/Shailendra Kumar/	Date Considered	02/03/2011
-----------------------	--------------------	--------------------	------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant,